美股异动 | 与诺和诺德(NVO.US)达成合作协议 Hims & Hers Health(HIMS.US)涨超21%

智通财经2025-04-29

智通财经APP获悉，周二，美国远程医疗公司Hims & Hers Health(HIMS.US)股价拉涨，截至发稿，该股涨超21%，报34.81美元。此前该公司宣布与丹麦制药巨头诺和诺德(NVO.US)达成合作协议，将通过其平台销售诺和诺德广受欢迎的减重药物Wegovy。与此同时，另一家远程医疗企业LifeMD(LFMD.US)股价也应声上涨超21%，该公司表示，所有剂量的Wegovy现已在其虚拟...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2531753197?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-04-29 21:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2531753197","market":"sh","top_or_hot":-1,"title":"美股异动 | 与诺和诺德(NVO.US)达成合作协议 Hims & Hers Health(HIMS.US)涨超21%","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，周二，美国远程医疗公司Hims & Hers Health(HIMS.US)股价拉涨，截至发稿，该股涨超21%，报34.81美元。此前该公司宣布与丹麦制药巨头诺和诺德(NVO.US)达成合作协议，将通过其平台销售诺和诺德广受欢迎的减重药物Wegovy。与此同时，另一家远程医疗企业LifeMD(LFMD.US)股价也应声上涨超21%，该公司表示，所有剂量的Wegovy现已在其虚拟...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1287837.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>美股异动 | 与诺和诺德(NVO.US)达成合作协议 Hims & Hers Health(HIMS.US)涨超21%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n美股异动 | 与诺和诺德(NVO.US)达成合作协议 Hims & Hers Health(HIMS.US)涨超21%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-04-29 21:55 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1287837.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，周二，美国远程医疗公司Hims & Hers Health(HIMS.US)股价拉涨，截至发稿，该股涨超21%，报34.81美元。此前该公司宣布与丹麦制药巨头诺和诺德(NVO.US)达成合作协议，将通过其平台销售诺和诺德广受欢迎的减重药物Wegovy。与此同时，另一家远程医疗企业LifeMD(LFMD.US)股价也应声上涨超21%，该公司表示，所有剂量的Wegovy现已在其虚拟...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1287837.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1093756325.SGD","symbol_name":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1287837.html","article_id":"2531753197","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2531753197","pubTimestamp":1745934918,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，周二，美国远程医疗公司Hims & Hers Health股价拉涨，截至发稿，该股涨超21%，报34.81美元。此前该公司宣布与丹麦制药巨头诺和诺德达成合作协议，将通过其平台销售诺和诺德广受欢迎的减重药物Wegovy。双方表示，此次打包产品的发布只是长期合作的第一步，预计将于本周内在Hims & Hers平台上线。这项合作对总部位于旧金山的Hims & Hers而言是一个关键转折点。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","BK4599":"减肥药","BK4588":"碎股","BK4196":"保健护理服务","BK4007":"制药","NVO":"诺和诺德","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","HIMS":"Hims & Hers Health Inc.","BK4585":"ETF&股票定投概念","BK4532":"文艺复兴科技持仓","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC"},"translate_title":"U.S. stock changes reach cooperation agreement with Novo Nordisk (NVO.US) Hims & Hers Health (HIMS.US) rose more than 21%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HIMS":1,"NVO":1},"content_text":"智通财经APP获悉，周二，美国远程医疗公司Hims & Hers Health(HIMS.US)股价拉涨，截至发稿，该股涨超21%，报34.81美元。此前该公司宣布与丹麦制药巨头诺和诺德(NVO.US)达成合作协议，将通过其平台销售诺和诺德广受欢迎的减重药物Wegovy。与此同时，另一家远程医疗企业LifeMD(LFMD.US)股价也应声上涨超21%，该公司表示，所有剂量的Wegovy现已在其虚拟诊疗平台上对自费患者开放。根据协议内容，诺和诺德旗下的直销平台NovoCare Pharmacy将可通过Hims & Hers网站进行访问，前提是用户需持有Hims & Hers会员身份，且所有剂量版本的Wegovy都将上线。双方表示，此次打包产品的发布只是长期合作的第一步，预计将于本周内在Hims & Hers平台上线。这项合作对总部位于旧金山的Hims & Hers而言是一个关键转折点。今年2月，美国FDA宣布Wegovy短缺问题结束，市场供应恢复，这一消息曾令Hims & Hers所销售的低价复合版本产品面临压力，并引发投资者对其业务模式的质疑。为应对这一局面，Hims & Hers曾于2024年5月推出复合版semaglutide产品，售价仅为原厂品牌产品的15%，即打85%折扣，大大吸引了关注减重药物的消费者。Hims & Hers首席执行官Andrew Dudum表示：“我们非常高兴能够与诺和诺德合作。该公司在临床医学方面拥有突破性的创新和强大的药物产品组合。”值得注意的是，此次合作宣布前数周，Hims & Hers才刚刚在其平台上开始销售礼来制药(LLY.US)广受欢迎的减重药tirzepatide的原厂版本。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation,movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2531753197","isCrawlerRequest":true}